Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19872121 | 0.88 | CYP19A1 (0.41) | CYP19A1CYP3A4LMNACYP1A2CYP11B1 | |
| SCHEMBL19879719 | 0.83 | CYP19A1 (0.41) | CYP19A1CYP3A4LMNACYP1A2CYP11B1 | |
| SCHEMBL20920914 | 0.82 | CYP19A1 (0.40) | CYP19A1CYP3A4KIF11 | |
| SCHEMBL21553999 | 0.81 | CYP19A1 (0.42) | CYP19A1CYP3A4LMNACYP1A2CYP11B1 | |
| SCHEMBL24065679 | 0.80 | CYP19A1 (0.47) | CYP19A1CYP3A4LMNACYP1A2CYP11B1 | |
| SCHEMBL26195181 | 0.78 | CYP19A1 (0.41) | CYP19A1CNR1CNR2KIF11 | |
| SCHEMBL19865805 | 0.78 | CYP19A1 (0.36) | CYP19A1 | |
| SCHEMBL24656639 | 0.76 | CYP19A1 (0.44) | CYP19A1CYP3A4LMNACYP1A2CYP11B1 | |
| SCHEMBL21370103 | 0.75 | CYP19A1 (0.39) | CYP19A1CYP3A4 | |
| SCHEMBL18427184 | 0.75 | CYP19A1 (0.49) | CYP19A1CYP3A4LMNACYP1A2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10786480-B2 | Combination therapy of a HIF-2-α inhibitor and an immunotherapeutic agent and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20190282535-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282535-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | HIF1AN, HIF1A, EGLN2 | CYP19A1 2096/4885CYP3A4 4620/4885LMNA 4219/4885 |
| US-10786480-B2 | Combination therapy of a HIF-2-α inhibitor and an immunotherapeutic agent and uses thereof | HIF1AN, HIF1A, EGLN2 | CYP19A1 2352/4885CYP3A4 4660/4885LMNA 4070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.